Ixekizumab

Phase 3 data presented at the European Academy of Dermatology and Venereology Congress demonstrated that treatment with Taltz resulted in a 75% improvement in Psoriasis Area of Severity Index score and static Physician Global Assessment of clear or almost clear skin at 12 weeks in pediatric patients with moderate to severe plaque psoriasis.

Eli Lilly and Co. reported that its phase 4 study, IXORA-R, met the primary endpoint of patients treated with Taltz showing statistically significant improvement in the Psoriasis Area Severity Index 100 score compared with patients on Tremfya at week 12.

Patients with psoriasis prescribed biologic agents are less likely to develop psychiatric illnesses compared with patients not prescribed biologic agents, which researchers concluded is due to treatment selection bias.